|
|
||||||||
Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss1
Department of Medicine, Hospital for Special Surgery-Weill Medical College of Cornell University, New York, NY 10021
The antiphospholipid syndrome (APS) is characterized by recurrent fetal loss, intrauterine growth restriction, and vascular thrombosis in the presence of antiphospholipid (aPL) Abs. Our studies in a murine model of APS induced by passive transfer of human aPL Abs have shown that activation of complement and recruitment of neutrophils into decidua are required for fetal loss, and emphasize the importance of inflammation in aPL Ab-induced pregnancy loss. In this study, we examine the role of TNF-
in pregnancy complications associated with aPL Abs in a murine model of APS. We show that aPL Abs are specifically targeted to decidual tissue and cause a rapid increase in decidual and systemic TNF-
levels. We identify the release of TNF-
as a critical intermediate that acts downstream of C5 activation, based on the fetal protective effects of TNF-
deficiency and TNF blockade and on the absence of increased TNF-
levels in C5-deficient mice treated with aPL Abs. Our results suggest that TNF-
links pathogenic aPL Abs to fetal damage and identify TNF blockade as a potential therapy for the pregnancy complications of APS.
This article has been cited by other articles:
![]() |
S. Monien, O. Kadecki, S. Baumgarten, A. Salama, T. Dorner, and H. Kiesewetter Use of Heparin in Women With Early and Late Miscarriages With and Without Thrombophilia Clinical and Applied Thrombosis/Hemostasis, December 1, 2009; 15(6): 636 - 644. [Abstract] [PDF] |
||||
![]() |
K Oku, T Atsumi, M Bohgaki, O Amengual, H Kataoka, T Horita, S Yasuda, and T Koike Complement activation in patients with primary antiphospholipid syndrome Ann Rheum Dis, June 1, 2009; 68(6): 1030 - 1035. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Giannakopoulos, F. Passam, Y. Ioannou, and S. A. Krilis How we diagnose the antiphospholipid syndrome Blood, January 29, 2009; 113(5): 985 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z Rotar, B Rozman, P. de Groot, M Sanmarco, Y Shoenfeld, P. Meroni, R Cervera, V Pengo, R Cimaz, T Avcin, et al. Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome? Lupus, January 1, 2009; 18(1): 53 - 60. [Abstract] [PDF] |
||||
![]() |
P. Soltesz, H. Der, K. Veres, R. Laczik, S. Sipka, G. Szegedi, and P. Szodoray Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction Rheumatology, November 1, 2008; 47(11): 1628 - 1634. [Abstract] [Full Text] [PDF] |
||||
![]() |
E Raschi, M. Borghi, C Grossi, V Broggini, S Pierangeli, and P. Meroni Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome Lupus, October 1, 2008; 17(10): 938 - 943. [Abstract] [PDF] |
||||
![]() |
J. Salmon and P. de Groot Pathogenic role of antiphospholipid antibodies Lupus, May 1, 2008; 17(5): 405 - 411. [Abstract] [PDF] |
||||
![]() |
Y. Shoenfeld, P. L. Meroni, and R. Cervera Antiphospholipid syndrome dilemmas still to be solved: 2008 status Ann Rheum Dis, April 1, 2008; 67(4): 438 - 442. [Full Text] [PDF] |
||||
![]() |
H. J. A. Carp and Y. Shoenfeld Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells an additional mechanism in a multi factorial process Rheumatology, October 1, 2007; 46(10): 1517 - 1519. [Full Text] [PDF] |
||||
![]() |
X.-X. Chen, Y.-Y. Gu, S.-J. Li, J. Qian, K.-K. Hwang, P. P. Chen, S.-L. Chen, and C.-D. Yang Some Plasmin-Induced Antibodies Bind to Cardiolipin, Display Lupus Anticoagulant Activity and Induce Fetal Loss in Mice J. Immunol., April 15, 2007; 178(8): 5351 - 5356. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Di Simone, P.L. Meroni, M. D'Asta, F. Di Nicuolo, M.C. D'Alessio, and A. Caruso Pathogenic role of anti-{beta}2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin Hum. Reprod. Update, March 1, 2007; 13(2): 189 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Martinez de la Torre, C. Buracchi, E. M. Borroni, J. Dupor, R. Bonecchi, M. Nebuloni, F. Pasqualini, A. Doni, E. Lauri, C. Agostinis, et al. Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6 PNAS, February 13, 2007; 104(7): 2319 - 2324. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Giannakopoulos, F. Passam, S. Rahgozar, and S. A. Krilis Current concepts on the pathogenesis of the antiphospholipid syndrome Blood, January 15, 2007; 109(2): 422 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
M D Lockshin Treating rheumatic diseases in pregnancy: dos and don'ts Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii58 - iii60. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Girardi, D. Yarilin, J. M. Thurman, V. M. Holers, and J. E. Salmon Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction J. Exp. Med., September 4, 2006; 203(9): 2165 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Gosman, H. I. Katcher, and R. S. Legro Obesity and the role of gut and adipose hormones in female reproduction Hum. Reprod. Update, September 1, 2006; 12(5): 585 - 601. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Boyson, N. Nagarkatti, L. Nizam, M. A. Exley, and J. L. Strominger Gestation stage-dependent mechanisms of invariant natural killer T cell-mediated pregnancy loss PNAS, March 21, 2006; 103(12): 4580 - 4585. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Simoncini, C. Sapet, L. Camoin-Jau, N. Bardin, J.-R. Harle, J. Sampol, F. Dignat-George, and F. Anfosso Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome Int. Immunol., April 1, 2005; 17(4): 489 - 500. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |